TCGA-A8-A085-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 37
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- MITOTIC_SPINDLE+0.310
- ESTROGEN_RESPONSE_EARLY+0.300
- E2F_TARGETS+0.280
- ANGIOGENESIS+0.270
- TGF_BETA_SIGNALING+0.250
- G2M_CHECKPOINT+0.240
- OXIDATIVE_PHOSPHORYLATION+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.240
- DNA_REPAIR+0.230
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.590
- INTERFERON_GAMMA_RESPONSE-0.550
- INTERFERON_ALPHA_RESPONSE-0.520
- INFLAMMATORY_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.410
- TNFA_SIGNALING_VIA_NFKB-0.400
- KRAS_SIGNALING_UP-0.390
- COMPLEMENT-0.380
- COAGULATION-0.280
- IL2_STAT5_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A04R-01A-41R-A109-07 | — | B | 0.867 |
| 2 | AUR-AD9E-TTM1-A-1-1-R-A542-39 | — | B | 0.827 |
| 3 | TCGA-E9-A1RE-01A-11R-A157-07 | — | B | 0.819 |
| 4 | SRR5903549 | — | cohortA4 | 0.816 |
| 5 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.816 |
| 6 | SRR6013533 | — | cohortSQ2 | 0.809 |
| 7 | MBCProject_6127_T2_RNA | — | B | 0.807 |
| 8 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.803 |
| 9 | sclc2008_S40.txt | — | cohortSC | 0.803 |
| 10 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |